Journal of Pulmonology and Clinical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Review Article - Journal of Pulmonology and Clinical Research (2022) Volume 5, Issue 5

Pulmonary hypertension and the role of the Management of cardiac dysfunction

Hickman Bailey*

Department of Medicine

*Corresponding Author:
Hickman Bailey
Department of Medicine
University of Chicago
United States
E-mail:hickmanB@uchicago.edu

Received:30-Aug-2022, Manuscript No. AAJPCR-22-81011; Editor assigned: 31-Aug-2022, PreQC No. AAJPCR-22-81011(PQ); Reviewed:14-Sep-2022, QC No. AAJPCR-22-81011; Revised:17-Sep-2022, Manuscript No. AAJPCR-22-81011(R); Published:24-Sep-2022, DOI: 10.35841/aaccr-5.5.124

Citation: Bailey H. Pulmonary hypertension and the role of the Management of cardiac dysfunction. J Pulmonol Clin Res. 2022; 5(5):124

Visit for more related articles at Journal of Pulmonology and Clinical Research

Abstract

Pulmonary hypertension is a pathophysiological state hemodynamically defined as the increase of the mean pulmonary arterial pressure above 25, or 30 mmHg at rest, measured by catheterization of the right heart. The majority of the time, laboratory results show polycythemia, right ventricle hypertrophy on the ECG, and sick branch characteristics on x-rays (echocardiography and biomarkers like B-type natriuretic peptide (BNP) and N-terminal pro-BNP hormones may be useful in detecting PH). Right atrial and ventricular hypertrophy, aberrant interventricular septal contraction, left ventricular diastolic dysfunction, decreased left ventricular size, and decreased systolic and end diastolic volumes can all be seen on an echocardiogram. Doppler tricuspid regurgitation confirmed.

Keywords

Pulmonary Hypertension, Hypertrophy, Catheterization.

Introduction

Progressive exercise dyspnea, sometimes accompanied by weariness and exhaustion, is the hallmark symptom of all forms of pulmonary hypertension. Since the symptoms are vague, there is frequently a long period of time—months or even years—between the start of symptoms and the diagnosis. Dyspnea when bending down (bendopnea), syncope, and other symptoms worsen as the condition progresses, with the latter occurring more frequently during or right after physical effort. Frequent syncope, even with minimal activity, indicates a life-threatening condition with a high fatality rate in individuals with pulmonary hypertension. The right ventricular filling pressures increase in cases of cardiac decompensation, together with the classic triad of cervical venous congestion, ascites, and edoema [1].

The patient response to treatment or unmet requirements in the day-to-day lives of patients and their caregivers are frequently missed by large-scale database research, which still collect information regarding medical treatment and disease management in a diverse patient population. In order to get insight into experiences of living with PH beyond clinical symptoms, a significant worldwide survey of 326 patients with PAH and 129 caregivers from five different European countries was conducted in 2013. Four areas affected by PAH were investigated in the survey, which included both qualitative one-on-one interviews and a quantitative opinion-based survey questionnaire (physical and practical, emotional, social and information needs) [2].

The findings demonstrated that PAH was associated with a large emotional and financial burden in addition to having a major physical and practical impact on patients' and their caregivers' everyday lives. Patients' closeness, relationships, emotional health, and social well-being were all significantly impacted by PAH. Physical, mental, and financial problems, as well as social isolation brought on by a lack of public understanding of the disease, were highlighted in a national survey of 114 Chinese PAH patients utilising semi-structured, face-to-face interviews [3].

Only a right cardiac catheterization can establish the diagnosis of pulmonary hypertension. However, not all individuals suspected of having pulmonary hypertension should have this invasive surgery. An invasive diagnostic procedure is typically not recommended in patients with chronic left heart disease or lung disease who show signs of pulmonary hypertension because there would typically be no consequences for their treatment, even though the indication is unquestionable in the case of suspected pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. The patients who are scheduled for heart or lung transplants, as well as those who have severe right heart overload or symptoms of severe pulmonary hypertension, are the exceptions to this guideline. This is especially true when there is a mismatch between the intensity of the symptoms and that of the right heart overload and the underlying condition is relatively modest. Since right cardiac catheterization should always be performed in a specialised facility, the patient should always be referred to one in the event of uncertainty [4].

All forms of pulmonary hypertension are clinically significant despite having different therapeutic implications since they are all linked to worsened symptoms and, almost universally, a higher chance of death. Although the treatment implications for pulmonary hypertension in left heart disease or lung disease are not yet evident, this is equally true for those conditions. Over the past three decades, people with pulmonary arterial hypertension have experienced a rise in life expectancy. When compared to the 1980s, this group's 3-year survival rate has improved. Patients with persistent thromboembolic pulmonary hypertension now have much better survival rates [5].

Conclusion

Although there has been significant progress in the treatment of PH, it is still a very dangerous illness that is not always simple to identify, manage, or avoid. Human resources, technical assistance, and a well-developed cardiac infrastructure are all required for these activities, both for adults and children. In our circumstances (Bosnia and Herzegovina), the causal treatment (heart and lung transplantation) is barely viable due to the high cost of specific and combination PAH medication. It is important to make efforts to raise awareness of this problem and establish conditions for adequate medical care, just like in other Western European nations, particularly those that are nearby.

References

  1. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension.. J Am Coll Cardiol. 2009; 54:S55–66.

    2. Indexed at, Google Scholar, Cross Ref

  2. Galie N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009; 30:2493–2537.

    3. Indexed at, Google Scholar, Cross Ref

  3. Pugh ME, Sivarajan L, Wang L, et al. Causes of Pulmonary Hypertension in the Elderly. Chest. 2014;146(1):159–66.

    4. Indexed at, Google Scholar, Cross Ref

  4. McGoon MD, Kane GC. Pulmonary Hypertension: Diagnosis and Management. Mayo Clinic Proceedings. 2009; 84(2):191–207.

    5. Indexed at, Google Scholar, Cross Ref

  5. Cogan JD, Pauciulo MW, Batchman AP, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174(5):590–8.

    6. Indexed at, Google Scholar, Cross Ref

Get the App